TY - JOUR
T1 - Flow cytometric analysis of myelodysplasia
T2 - Pre-analytical and technical issues—Recommendations from the European LeukemiaNet
AU - van der Velden, Vincent H. J.
AU - Preijers, Frank
AU - Johansson, Ulrika
AU - Westers, Theresia M.
AU - Dunlop, Alan
AU - Porwit, Anna
AU - Béné, Marie C.
AU - Valent, Peter
AU - te Marvelde, Jeroen
AU - Wagner-Ballon, Orianne
AU - Oelschlaegel, Uta
AU - Saft, Leonie
AU - Kordasti, Sharham
AU - Ireland, Robin
AU - Cremers, Eline
AU - Alhan, Canan
AU - Duetz, Carolien
AU - Hobo, Willemijn
AU - Chapuis, Nicolas
AU - Fontenay, Michaela
AU - Bettelheim, Peter
AU - Eidenshink-Brodersen, Lisa
AU - Font, Patricia
AU - Loken, Michael R.
AU - Matarraz, Sergio
AU - Ogata, Kiyoyuki
AU - Orfao, Alberto
AU - Psarra, Katherina
AU - Subirá, Dolores
AU - Wells, Denise A.
AU - Della Porta, Matteo G.
AU - Burbury, Kate
AU - Bellos, Frauke
AU - Weiß, Elisabeth
AU - Kern, Wolfgang
AU - van de Loosdrecht, Arjan
N1 - Funding Information: Austrian Science Fund, Grant/Award Number: F4704‐B20; Horizon 2020 Framework Programme, Grant/Award Number: 634789 Funding information Funding Information: Peter Valent was supported by the Austrian Science Fund, grant F4704‐B20. Nicolas Chapuis and Michaela Fontenay were supported by the European Union's Horizon 2020 research and innovation program under grant agreement No. 634789. Publisher Copyright: © 2021 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.
PY - 2023/1/15
Y1 - 2023/1/15
N2 - Background: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.
AB - Background: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.
KW - ELN
KW - MDS
KW - flow cytometry
KW - pre-analytic issues
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85128496758&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34894176
U2 - https://doi.org/10.1002/cyto.b.22046
DO - https://doi.org/10.1002/cyto.b.22046
M3 - Article
C2 - 34894176
SN - 1552-4949
VL - 104
SP - 15
EP - 26
JO - Cytometry Part B - Clinical Cytometry
JF - Cytometry Part B - Clinical Cytometry
IS - 1
ER -